Price
No data yet.
Social Signal Score
Analyst Ratings
8 analystsRevenue
$1.05MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Gavin MacBeath
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 138
- Beta
- 1.07
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -6.15
Financials
Revenue
$1.05M+262.4%Net Income
$-30.36MEBITDA
$-28.96MFree Cash Flow
$-28.03MEPS (diluted)
$-0.23Shares Outstanding (diluted)
129.95M+442.8%Operating Expenses
$31.54MCash & Debt
$100.16MReturn of Capital
$0.00Revenue by Segment (annual)
$10.32MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $10.32M | $-129.77M | $-1.00 |
| 2024 | $2.82M | $-127.50M | $-1.14 |
| 2023 | $21.05M | $-89.22M | $-1.36 |
| 2022 | $13.54M | $-66.22M | $-2.74 |
| 2021 | $10.14M | $-48.63M | $-2.03 |
| 2020 | $1.08M | $-26.13M | $-1.04 |
| 2019 | $0.00 | $-13.66M | $-0.53 |
Valuation
TCRXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
143+377.78%Social Signal Score
Mentions (4)
- Newsseekingalpha.com·33d ago·Positive
TScan Therapeutics, Inc. (TCRX) Discusses Strategic Refocus on In Vivo Cell Therapy for Solid Tumors and Pausing of Phase III Heme Study Transcript TScan Therapeutics, Inc. (TCRX) Discusses Strategic Refocus on In Vivo Cell Therapy for Solid Tumors and Pausing of Phase III Heme Study Transcript
View source ↗ - Newsbenzinga.com·33d ago·Negative
TScan Reorganizes Pipeline Priorities, Implements Workforce Reduction TScan Therapeutics Inc. (NASDAQ:TCRX) on Wednesday announced a major corporate reorganization to prioritize its in vivo solid tumor pipeline, prompting a workforce reduction of approximately 75%.
View source ↗ - Newsglobenewswire.com·34d ago·Negative
TScan Therapeutics Announces Strategic Reorganization to Focus on in vivo Cell Therapy for Solid Tumors Advances two in vivo-engineered TCR-T candidates for solid tumors to IND-enabling studies with plans to initiate Phase 1 development in Q4 2027 Reports updated data from Cohort C of the Phase 1 ALLOHA™ study; 100% (13/13) patients currently being tracked show complete donor chimerism Pauses further enrollment in Phase 3 ALLOHA-2™ study of TSC-101 due to insufficient capital; allowing data to m
View source ↗ - Newsglobenewswire.com·55d ago·Negative
TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update First patient dosed in Phase 3 ALLOHA-2™ study; topline readout expected mid-2028 Shared positive initial data from Cohort C of Phase 1 ALLOHA™ study, validating internal commercial-ready manufacturing process Cash and cash equivalents fund operations into the second quarter of 2027 WALTHAM, Mass., Aug. 12, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology
View source ↗
Earnings
Wed, Nov 11(in 5 weeks)
Consensus estimate $-0.18 per share
Typical surprise +7.1% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 12$-0.23 vs $-0.25beat
- Wed, May 6$-0.22 vs $-0.22beat
- Wed, Mar 4$-0.18 vs $-0.27beat
- Wed, Nov 12$-0.28 vs $-0.35beat
- Tue, Aug 12$-0.28 vs $-0.28beat
- Tue, May 6$-0.26 vs $-0.28beat
Estimates and results for TCRX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by TCRX officers and directors.
- Bought
- $4.0m
- Sold
- $1.0m
19 trades
4 trades
- Lynx1 Capital Management Lpbought
- Lynx1 Capital Management Lpbought
- Lynx1 Capital Management Lpbought
- Lynx1 Capital Management Lpbought
- Lynx1 Capital Management Lpbought
- Lynx1 Capital Management Lpbought
- Lynx1 Capital Management Lpbought
- Lynx1 Capital Management Lpbought
77 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in TCRX.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.